GlassScriptPhysician profile
Kendall N Dorie
NPI 1164081253
$3,701.15
in general payments reported to CMS, 2019-2025
29 companies · $730 in 2025
The $730 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $655 · 2022: $375 · 2023: $1,055 · 2024: $887 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,671.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $579.39 | 2021-2025 | |
| Alkermes, INC. | $290.87 | 2021-2025 | Lybalvi, Vivitrol, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $284.19 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $243.77 | 2021-2025 | Airsupra |
| Halozyme INC | $219.92 | 2023 | |
| Biomerieux INC | $203.00 | 2025 | |
| Amgen INC. | $192.75 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $161.65 | 2023-2025 | Spravato |
| Abbott Laboratories | $150.80 | 2023 | Freestyle Libre 3 |
| Braeburn INC. | $143.77 | 2024-2025 | Brixadi |
| Gilead Sciences, INC. | $143.28 | 2023-2024 | Epclusa |
| Indivior INC. | $122.83 | 2021-2025 | Sublocade |
| Glaxosmithkline, LLC. | $117.79 | 2021 | |
| Eisai INC. | $112.24 | 2024 | |
| Supernus Pharmaceuticals, INC. | $100.02 | 2023-2024 | Xyosted, Qelbree, Qelbree |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $95.94 | 2024 | Barostim Neo System |
| Sunovion Pharmaceuticals INC. | $76.76 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $69.34 | 2021-2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $68.86 | 2023-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $68.78 | 2024-2025 | Hetlioz, Fanapt |
| Corium, LLC | $49.18 | 2023-2024 | Azstarys |
| Axsome Therapeutics, INC. | $40.67 | 2024 | Auvelity |
| Exact Sciences Corporation | $37.02 | 2025 | The Cologuard Plus Collection Kit |
| Harmony Biosciences LLC | $31.63 | 2025 | |
| Revance Therapeutics, INC. | $24.53 | 2025 | Daxxify |
| Lundbeck LLC | $20.36 | 2023 | Rexulti |
| Tris Pharma INC | $19.70 | 2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $17.01 | 2025 | Capvaxive, Gardasil 9 |
| Neurocrine Biosciences, INC. | $15.10 | 2023 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall Dorie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.